A new study is the first using multigene panel testing to examine potentially important mutations among patients with early-onset colorectal cancer. Here’s how it suggests screening should change.
While it is still early in the evolution of transanal total mesorectal excision (TaTME), the technique is gaining traction as the go-to procedure in select cases, Cleveland Clinic colorectal surgeons report.
A recent survey of trainee colonoscopists and their primary care peers showed they have poor recollection of colorectal cancer screening and surveillance guidelines, despite having recently studied them.
Until now, there has been no specific clinical sign that a person has the colorectal cancer predisposition syndrome called MYH-associated polyposis (MAP). Dr. James Church explains his findings.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
As a GI, how do you make sound judgments to balance cancer prevention and quality of life in patients with inherited colorectal cancer predisposition syndromes? Here Dr. James Church explains Cleveland Clinic’s approach.
Research just presented at DDW 2016 found patients who only had surgery to treat postop, node-positive, stage III rectal cancer experienced significantly poorer outcomes compared with those who also had adjuvant treatment.
Cleveland Clinic research uncovers the influence of cancer-associated fibroblasts and secretion of the cytokine IL-17A on stem cell renewal, chemotherapy resistance and tumor spread in colorectal cancer.
A new generation of leaders in the field of colorectal surgery at Cleveland Clinic is finding solutions for patients with complex cases who have been told, “It can’t be done.” Discover more
From a brand-new, 377,000-square-foot cancer building opening in 2017 to standardizing care, discover how Cleveland Clinic is changing the way it delivers colorectal cancer care.
Cleveland Clinic colorectal surgeons are partnering with colleagues nationwide through the OSTRiCh consortium to help improve the care rectal cancer patients receive and to improve outcomes.